Emerging Therapies for the Management of Castration-Sensitive Prostate Cancer
Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence, and performance gaps exist in the optimal management of metastatic castration-sensitive prostate cancer (mCSPC).
This webinar addresses some of the challenges in optimal sequencing of care in mCSPC and strategies for translating new research into patient care strategies.
Pedro C. Barata, MD, MSC
Assistant Professor, Deming Department of Medicine Division of Hematology/Oncology, Genitourinary Cancers
Lisa M. Holle, PharmD, BCOP, FHOPA
Associate Clinical Professor, UConn School of Pharmacy
Associate Professor, UConn School of Medicine
VIEW ON-DEMAND RECORDING
This activity was in collaboration with the Association of Community Cancer Centers (ACCC).